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Mesenchymal stem cell transplantation (MSCT) has
been used to treat human diseases, but the detailed
mechanisms underlying its success are not fully un-
derstood. Here we show that MSCT rescues bone
marrow MSC (BMMSC) function and ameliorates
osteopenia in Fas-deficient-MRL/lpr mice. Mecha-
nistically, we show that Fas deficiency causes
failure of miR-29b release, thereby elevating intracel-
lular miR-29b levels, and downregulates DNA meth-
yltransferase 1 (Dnmt1) expression in MRL/lpr
BMMSCs. This results in hypomethylation of the
Notch1 promoter and activation of Notch signaling,
in turn leading to impaired osteogenic differentiation.
Furthermore, we show that exosomes, secreted due
to MSCT, transfer Fas to recipient MRL/lpr BMMSCs
to reduce intracellular levels of miR-29b, which re-
sults in recovery of Dnmt1-mediated Notch1 pro-
moter hypomethylation and thereby improves MRL/
lpr BMMSC function. Collectively our findings un-
ravel the means by which MSCT rescues MRL/lpr
BMMSC function through reuse of donor exosome-
provided Fas to regulate the miR-29b/Dnmt1/Notch
epigenetic cascade.
INTRODUCTION
Systemic mesenchymal stem cell transplantation (MSCT) has
been successfully used to treat a variety of human diseases,
such as systemic lupus erythematosus (SLE), graft versus host
disease (GvHD), rheumatoid arthritis, myocardial infarction, liver
fibrosis, inflammatory bowel disease, and multiple sclerosis (Au-
gello et al., 2007; Gonza´lez et al., 2009; Hatzistergos et al., 2010;
Le Blanc et al., 2004; Liang et al., 2009; Ren et al., 2012; Sakaida
et al., 2004; Sun et al., 2009). Multiple therapeutic mechanisms
may contribute to MSCT-based therapies, including paracrine
secretion of cytokines (Choi et al., 2011; Ne´meth et al., 2009)
and interplay between MSCs and immune cells (Akiyama et al.,606 Cell Metabolism 22, 606–618, October 6, 2015 ª2015 Elsevier In2012). However, the details of thesemechanisms are not fully un-
derstood. Although most systemically infused MSCs fail to
engraft into recipient organs, a single administration of MSCT
is capable of perpetual amelioration of disease phenotypes
(Akiyama et al., 2012; Le Blanc et al., 2008; Peng et al., 2011;
Sun et al., 2009; Wang et al., 2012), suggesting that MSCT
may target recipient cellular andmolecular regulation tomaintain
MSCT-based therapeutic effects.
Epigenetic modifications encompass a wide range of heritable
molecular changes and are often associated with human dis-
eases (Kelly et al., 2010; Portela and Esteller, 2010). Epigenetic
aberrations may play an important role in the maintenance of
pathological status in some diseases (Bechtel et al., 2010;
Golden et al., 2013; Zhang et al., 2011). Therapeutic approaches
aimed at reversing epigenetic aberrations can sustain therapeu-
tic effects (Tsai et al., 2012b). This evidence suggests that epige-
netic modifications may play a crucial role in generating an
epigenetic ‘‘memory’’ thatmaintains physiological and patholog-
ical status. In this study, we show that MSCT rescues impaired
bone marrow MSCs (BMMSCs) and osteoporotic phenotype in
Fas-deficientMRL/lprmice, whichmodel SLE, via reuse of donor
exosome-derived Fas, to recover Fas functions.RESULTS
MSCT Rescues Impaired BMMSCs and Osteoporotic
Phenotype in Recipient MRL/lpr SLE Mice
SLE is an autoimmune disease with the potential to damagemul-
tiple organs, such as the musculoskeletal, renal, cardiovascular,
neural, and cutaneous systems (Rahman and Isenberg, 2008).
MSCT can effectively rescue the disease phenotypes in SLE pa-
tients (Sun et al., 2009). Although the MSCs delivered during
treatment usually fail to engraft to a significant degree in recipient
organs, a single administration of MSCT is capable of sustained
amelioration of disease phenotypes in a mouse model of SLE
(MRL/lpr mice) (Sun et al., 2009). We revealed that BMMSCs
derived from MRL/lprmice showed a reduced capacity for oste-
ogenic differentiation, as indicated by decreased calcium nodule
formation and expression of osteogenic markers Runx2 and ALP
when cultured under osteogenic inductive conditions (Figure 1A
and see Figure S1A available online). We further revealed thatc.
Figure 1. MSC Transplantation (MSCT) Rescued Impaired BMMSC Functions andOsteoporotic Phenotype inMRL/lprMice via Regulation of
DNA Methylation Profile
(A) Alizarin red staining showedmineralized nodule formation of BMMSCs derived fromwild-typeC3H/HeJmice (C3H/HeJ), MRL/lprmice (MRL/lpr), andMRL/lpr
mice at 4 weeks post-MSCT. n = 5. Western blot showed expression of Runx2 and ALP in BMMSCs. b-actin was used as a loading control.
(B) H&E staining showed formation of new bone (B) and bone marrow (BM) around HA/TCP (HA) carrier when BMMSCs were implanted into immunocompro-
mised mice. n = 5.
(C) mCT analysis of bone mineral density (BMD) and bone volume/total volume (BV/TV) of femurs. n = 5.
(D) MA plot showed global methylation patterns of gene promoters in BMMSCs, as assessed by DNA methylation microarray.
(E) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 5. Western blot showed expressions of Runx2 and ALP in BMMSCs.
(F) H&E staining showed formation of new bone (B) and bonemarrow (BM) aroundHA/TCP (HA) carrier whenBMMSCswere implanted into immunocompromised
mice. n = 5.
(G) mCT analysis of BMD and BV/TV of femurs. n = 5. All results are representative of data generated in three independent experiments except DNA methylation
microarray analysis. Statistical significance was determined with one-way analysis of variance (ANOVA). **p < 0.01; *p < 0.05. Error bars are mean ± SD; 200 mm
(B and F), 1 mm (C and G).MRL/lpr BMMSCs exhibited significantly reduced capacities to
generate new bone when implanted into immunocompromised
mice subcutaneously using hydroxyapatite tricalcium phosphate
(HA/TCP) as a carrier (Figures 1B and S1B). The impaired func-
tion of MRL/lprBMMSCswas rescued byMSCT at both 4 weeks
and 12 weeks postinfusion, as indicated by increased mineral-
ized nodule formation, expression of Runx2 and ALP, and in vivo
bone formation when implanted into immunocompromised mice
(Figures 1A, 1B, S1A, and S1B). These results indicate that
MSCT is capable of long-term rescue of the impaired functionCellof recipient BMMSCs in MRL/lpr mice. When compared with
wild-type control mice (C3H/HeJ), the femurs of MRL/lpr mice
showed an osteoporotic phenotype, as indicated by significantly
reduced trabecular bone volume, bone mineral density (BMD),
and bone volume/total volume (BV/TV) (Figures 1C and S1C).
Moreover, MRL/lpr mice showed reduced capacity to form
new bone, as assessed by dynamic bone histomorphometric
parameters, including mineral apposition rate (MAR) and bone
formation rate per bone surface (BFR/BS) values using double
calcein labeling (Figures S1D and S1E). At 4 weeks post-MSCT,Metabolism 22, 606–618, October 6, 2015 ª2015 Elsevier Inc. 607
osteoporotic phenotypes of MRL/lpr mice, including trabecular
bone volume, BMD, and BV/TV, were rescued (Figure 1C).
More importantly, MSCT-mediated rescue of osteoporotic phe-
notypes was retained until at least 12 weeks post-MSCT (Fig-
ure S1C). Meanwhile, the impaired capacity to form new bone
seen in MRL/lpr mice was rescued at 4 and 12 weeks post-
MSCT (Figures S1D and S1E). These data suggest that a single
administration of MSCT is capable of rescuing osteoporotic phe-
notypes and maintaining the therapeutic effects for a sustained
period of time.
Since bone homeostasis is maintained by the interplay be-
tween bone resorption by osteoclasts and bone formation by os-
teoblasts, we confirmed that elevated levels of RANKL and
reduced levels of OPG in MRL/lprmice were rescued at 4 weeks
post-MSCT (Figures S1F and S1G) as well as at 12 weeks post-
MSCT (Figures S1H and S1I), suggesting that MSCT improves
function of both osteoblast and osteoclast lineages.
DNA Methylation Contributes to MSCT-Mediated
Functional Improvement of Recipient MRL/lpr BMMSCs
Since our data showed that MSCT resulted in long-term func-
tional improvement of MRL/lpr BMMSCs (Figures S1A–S1C
and S1E), we next examined whether epigenetic regulation,
such as DNA methylation, is involved in MSCT-mediated func-
tional recovery of recipient MRL/lpr BMMSCs. DNA methylation
microarray analysis showed that the global methylation pattern
of MRL/lpr BMMSC gene promoters, as indicated by the shape
of the MA-plot, was significantly different from that of control
BMMSCs (Figure 1D). At 1 week post-MSCT, the altered global
methylation pattern in MRL/lpr BMMSCs was partially rescued,
showing a similar pattern to that observed in control BMMSCs
(Figure 1D). Moreover, using unsupervised clustering analysis,
we revealed that the methylation pattern of BMMSCs derived
from MSCT-treated MRL/lpr mice was more strongly correlated
with that of control BMMSCs than with that of untreated MRL/lpr
BMMSCs (Figure S2A). In addition, whole-genome methylation
status analysis showed that the reduced number of methylated
peaks and sum of methylated peaks in MRL/lpr BMMSCs were
rescued by MSCT (Figures S2B and S2C), confirming that
MSCT is able to rescue the global hypomethylation profile of
the recipient BMMSCs.
In order to assess whether the global hypomethylation status
contributes to BMMSC impairment in MRL/lpr mice, we used
5-Azacytidine, a demethylating agent, to induce a global hypo-
methylation status in wild-type BMMSCs, mimicking MRL/lpr
BMMSCs. We found that 5-Azacitidine treatment was able to
inhibit osteogenic differentiation of BMMSCs, as indicated by
reduced capacity to form mineralized nodules (Figure S2D). To
examine whether rescue of the global hypomethylationin MRL/
lprBMMSCs contributes toMSCT-mediated therapeutic effects,
we used 5-Azacytidine to treat MRL/lpr mice at 1 week post-
MSCT and found that 5-Azacytidine treatment blocked MSCT-
mediated therapeutic effects, including the improved in vitro
mineralized nodule formation, expression of Runx2 and ALP,
in vivo new bone formation, trabecular bone volume, BMD,
and BV/TV of the femurs (Figures 1E–1G) seen after MSCT in
MRL/lpr mice without 5-Azacytidine treatment. Also, 5-Azacyti-
dine treatment blocked MSCT-mediated therapeutic improve-
ment of the capacity for new bone formation in MRL/lpr mice,608 Cell Metabolism 22, 606–618, October 6, 2015 ª2015 Elsevier Inas assessed by MAR and BFR/BS values (Figure S2E). These re-
sults indicate that global DNA methylation status may be essen-
tial for MSCT-mediated rescue of recipient BMMSC function and
osteoporotic phenotype in MRL/lpr mice.
Notch1 Promoter Methylation Contributes to MSCT-
Mediated Functional Improvement of Recipient MRL/lpr
BMMSCs
Given thatMSCT rescues the hypomethylation status in recipient
BMMSCs, we next evaluated whether DNA hypomethylation
occurred in any specific gene in recipient BMMSCs that may
contribute to MSCT-mediated therapeutic rescue. Based on
DNA methylation array analysis, we found that, compared with
wild-type BMMSCs, several of the Notch genes, including
Notch1, Notch2, Jag1, Jag2, DLL4, and Hes5, were hypomethy-
lated in MRL/lpr BMMSCs and that this hypomethylation status
was rescued byMSCT (Figures S2F–S2K). Since Notch signaling
has been demonstrated to regulate bone mesenchymal cell self-
renewal and differentiation (Dong et al., 2010; Hilton et al., 2008),
we used bisulfite genomic sequencing analysis to show that the
promoter region of Notch1 (1,053/834) was hypomethylated
and its methylation status was rescued after MSCT (Figures 2A,
S2L, and S2M). Moreover, we revealed that MRL/lpr BMMSCs
had elevated expression levels of Notch1, Notch2, Jag1, and
Notch1 intracellular domain (NICD) compared to wild-type
BMMSCs; however, this elevation of Notch-related gene expres-
sion was reduced by MSCT (Figure 2B). These data indicate that
hypomethylation led to the activation of Notch signaling, which
was rescued by MSCT (Figure 2B).
We thus hypothesized that hypomethylation of the promoters
of Notch1 activated Notch signaling, resulting in reduced osteo-
genic differentiation in MRL/lpr BMMSCs. To test this hypothe-
sis, we treated MRL/lpr BMMSCs with DAPT, a Notch signaling
inhibitor (Figures S3A and S3B). DAPT treatment partially
rescued osteogenic differentiation capacity, as indicated by
mineralized nodule formation, expression of osteogenic markers
Runx2 and ALP (Figure 2C), and in vivo bone formation (Fig-
ure 2D). To further confirm the role of Notch signaling in the regu-
lation of BMMSC functions, we treated MRL/lprmice with DAPT
and found that DAPT treatment rescued MRL/lpr BMMSC func-
tion, as indicated by improved in vitro mineralized nodule forma-
tion, expression of Runx2 and ALP (Figure 2E) and in vivo bone
formation (Figure 2F). Moreover, in vivo DAPT treatment partially
rescued the osteoporotic phenotype and new bone formation
capacity of MRL/lpr mice, as indicated by increased trabecular
bone volume, BMD, BV/TV, MAR, and BFR/BS (Figures 2G
and S3C). Moreover, DAPT treatment reversed inhibitive effects
of 5-Azacytidine onMSCT-mediated therapeutic effects, as indi-
cated by improved trabecular bone volume, BMD, BV/TV, miner-
alized nodule formation, and expression of Runx2 and ALP (Fig-
ures S3D and S3E). In order to further confirm the role of Notch1
in regulating bonemass, we used siRNA injection to knock down
Notch1 expression and found that in vivo knockdown of Notch1
(Figure S3F) partially rescued the osteoporotic phenotype in
MRL/lprmice, as indicated by elevated trabecular bone volume,
BMD, and BV/TV values (Figure S3G). Moreover, in vitro Notch1
knockdown partially rescued impaired BMMSC function in MRL/
lprmice, as indicated by increased mineralized nodule formation
and expression of Runx2 and ALP (Figure S3H). These datac.
Figure 2. MSCT Inhibited Notch Signaling in Recipient MRL/lpr BMMSCs via Regulating DNA Methylation in Notch1 Promoter Region
(A) Bisulfite genomic sequencing analysis of BMMSC Notch1 promoter region. Each box is representative of the indicated BMMSC sample; each row of dots is
representative of the CpG island in the Notch1 promoter region; each dot is representative of a single CpG. Empty dots indicate unmethylated CpGs; black dots
indicate methylated CpGs. Each row represents a single sequenced clone (ten for each sample).
(B) Western blot showed Notch1, Notch2, Jag1, and NICD expression in BMMSCs.
(C) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 5. Western blot showed expressions of Runx2 and ALP in BMMSCs.
(D) H&E staining showed formation of new bone (B) and bone marrow (BM) around HA/TCP (HA) carrier when BMMSCs were implanted into immunocompro-
mised mice. n = 5.
(E) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 5. Western blot showed expression of Runx2 and ALP in BMMSCs.
(F) H&E staining showed formation of new bone (B) and bonemarrow (BM) aroundHA/TCP (HA) carrier whenBMMSCswere implanted into immunocompromised
mice. n = 5.
(G) mCT analysis of BMDandBV/TV of femurs. n = 5. All results are representative of data generated in three independent experiments. Statistical significancewas
determined with one-way ANOVA. **p < 0.01. Error bars are mean ± SD, 200 mm (D and F), 1 mm (G).indicate that DNA methylation modifications of Notch signaling
play an important role in the impairment of MRL/lpr BMMSCs
and that the function of these BMMSCs can be rescued by
MSCT.
Hypomethylation of Notch1 Is Regulated by miR-29b-
Mediated Downregulation of Dnmt1
We next aimed to gain insights into how the hypomethylation of
theNotch1 promoters was regulated byMSCT. DNAmethylation
of CpG dinucleotides is catalyzed by at least three different DNA
methyltransferases (DNMTs), including Dnmt1 for methylation
maintenance and Dnmt3a and Dnmt3b for de novo methylationCell(Denis et al., 2011). The DNMTs are essential for maintaining
the methylation pattern in stem cells and for regulating their
self-renewal and differentiation (Challen et al., 2012; Tsai et al.,
2012a). We observed downregulation of Dnmt1, Dnmt3a, and
Dnmt3b in MRL/lpr BMMSCs when compared to control
BMMSCs, as indicated by western blot (Figure 3A). MSCT
rescued the downregulated Dnmt1, Dnmt3a, and Dnmt3b in
MRL/lpr BMMSCs (Figure 3A). Therefore, we aimed to evaluate
whether elevated expression of DNMTs as a result of MSCT con-
tributes to the rescue of hypomethylation of theNotch1 promoter
in MRL/lpr BMMSCs. Using an siRNA knockdown approach, we
demonstrated that Dnmt1-siRNA, but not Dnmt3a-siRNA orMetabolism 22, 606–618, October 6, 2015 ª2015 Elsevier Inc. 609
Figure 3. MSCT Rescued Hypomethylation of the Notch Gene Promoter in Recipient MRL/lpr BMMSCs via Upregulation of Dnmt1
(A) Western blot showed Dnmt1, Dnmt3a, and Dnmt3b expression in BMMSCs.
(B) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 4.
(C) Western blot showed Runx2 and ALP expression in BMMSCs.
(D and G) Bisulfite genomic sequencing analysis of BMMSC Notch1 promoter region.
(E and H) Western blot showed Notch1, Notch2, and NICD expression in BMMSCs.
(F and I) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 4. Western blot showed Runx2 and ALP expression in BMMSCs. All results
are representative of data generated in three independent experiments. Statistical significance was determined with one-way ANOVA. **p < 0.01. Error bars are
mean ± SD.Dnmt3b-siRNA, inhibited BMMSCosteogenic differentiation and
expression of Runx2 and ALP (Figures 3B, 3C, and S4A–S4C).
Thus, we focused on examining the functional role of Dnmt1 in
MSCT-treated MRL/lpr mice. To evaluate whether Dnmt1 regu-
lates BMMSC function throughDNAmethylation of Notch genes,
we demonstrated that knockdown of Dnmt1 by siRNA induced
hypomethylation of the Notch1 promoter (Figure 3D) and acti-
vated Notch signaling, including upregulation of Notch1, Notch2,
and NICD (Figure 3E), mimicking the altered methylation and
expression of the Notch1 gene in MRL/lpr BMMSCs. Moreover,
inhibition of Notch signaling by DAPT treatment partially rescued
the Dnmt1 knockdown-induced impairment of BMMSCs, as
indicated by in vitro osteogenic differentiation with mineralized
nodule formation and expression of Runx2 and ALP (Figure 3F).
Additionally, we showed that inhibition of methylation by 5-Aza-
cytidine treatment downregulated Dnmt1 and upregulated
Notch1 and NICD expression in BMMSCs (Figure S4D). These
data demonstrate that Dnmt1-mediated Notch1 promoter DNA
methylation contributes to MSCT-induced functional recovery610 Cell Metabolism 22, 606–618, October 6, 2015 ª2015 Elsevier Inof recipient MRL/lpr BMMSCs. Next, we showed that upregula-
tion of Dnmt1 in MRL/lpr BMMSCs rescued several defects: hy-
pomethylation of the Notch1 promoter, upregulated expression
of Notch1, Notch2, and NICD, impaired in vitro osteogenic differ-
entiation and reduced expression of Runx2 and ALP (Figures
3G–3I and S4E).
Given that Dnmt1 regulates the Notch1 promoter methylation
and contributes to functional recovery of recipient MRL/lpr
BMMSCs, we next determined how Dnmt1 expression is regu-
lated in MRL/lpr BMMSCs, and in particular whether microRNAs
are involved in this process. MicroRNAs are noncoding 22 nt
RNAs which serve as repressors of gene expression at the post-
transcriptional regulation level and are involved in some disease
processes (Soifer et al., 2007). In order to evaluate whether
microRNAs are involved in the regulation of Dnmt1 expression,
we used microRNA microarray analysis to show that miR-29b,
which was previously demonstrated to indirectly inhibit Dnmt1
expression and induce global hypomethylation modifications
(Garzon et al., 2009; Qin et al., 2013), was upregulated inMRL/lprc.
Figure 4. MSCT Governed Dnmt1-Mediated DNA Methylation of the Notch1 Promoter via Regulating Intracellular Levels of miR-29b
(A and B) Real-time PCR showed miR-29b expression in BMMSCs. n = 5.
(C) Western blot showed Notch1 and Dnmt1 expression in BMMSCs.
(D) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 5. Western blot showed Runx2 and ALP expression in BMMSCs.
(E) H&E staining showed formation of new bone (B) and bone marrow (BM) around HA/TCP (HA) carrier when BMMSCs were implanted into immunocompro-
mised mice. n = 5.
(F) mCT analysis showed BMD and BV/TV of femurs. n = 5.
(G) Bisulfite genomic sequencing analysis of BMMSC Notch1 promoter region.
(H) Western blot showed Notch1, Notch2, Jag1, and NICD expression in BMMSCs.
(I) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 4. Western blot showed Runx2 and ALP expression in BMMSCs. All results are
representative of data generated in three independent experiments. Statistical significance was determined with one-way ANOVA. **p < 0.01. Error bars are
mean ± SD, 200 mm (E), 1 mm (F).BMMSCs and downregulated after MSCT (Figures 4A and S4F).
Based on these data, we hypothesized that miR-29b might
govern Dnmt1-mediated DNA methylation modifications of the
Notch1 promoter, leading to the functional recovery of recipient
MRL/lpr BMMSCs after MSCT. In accordance with previous
studies (Garzon et al., 2009; Qin et al., 2013), we found that
in vitro miR-29b inhibitor treatment reduced expression of
miR-29b and increased Dnmt1 expression in BMMSCs, as indi-
cated by real-time PCR and western blot (Figures S4G–S4I).
MiR-29b inhibitor treatment also promoted in vitro osteogenic
differentiation of BMMSCs, as indicated by mineralized nodule
formation (Figure S4J). In order to evaluate the functional roleCellof miR-29b in vivo, we treated MRL/lprmice with miR-29b inhib-
itor and found that the treatment reduced the levels of miR-29b
and Notch1 while elevating expression levels of Dnmt1 in MRL/
lpr BMMSCs (Figures 4B and 4C). Inhibitor treatment also
increased mineralized nodule formation, assessed by alizarin
red staining, and increased expression of Runx2 and ALP, as-
sessed by western blot analysis (Figure 4D). When implanted
into immunocompromised mice, BMMSCs derived from miR-
29b inhibitor-treated MRL/lpr mice showed increased capacity
for in vivo new bone formation (Figure 4E). In addition, in vivo
miR-29b inhibitor treatment rescued the osteoporotic phenotype
and new bone formation capacity of MRL/lpr mice, as indicatedMetabolism 22, 606–618, October 6, 2015 ª2015 Elsevier Inc. 611
by increased trabecular bone volume, BMD, BV/TV, MAR, and
BFR/BS (Figures 4F and S4K). Meanwhile, introduction of syn-
thesized double-stranded miR-29b into naive BMMSCs mimics
the effect of physiological modulators that increase miR-29b
expression in BMMSCs (Figure S4L). MiR-29b mimics
decreased the expression levels of Dnmt1 in BMMSCs, as indi-
cated by real-time PCR and Western blot (Figures S4M and
S4N). MiR-29b mimics also reduced in vitro osteogenic differen-
tiation of BMMSCs, as indicated by mineralized nodule forma-
tion (Figure S4O). In order to explore whether miR-29b-mediated
DNA methylation modifications are associated with regulation of
Notch signaling, we demonstrated that miR-29bmimics resulted
in hypomethylation of the Notch1 promoter (Figure 4G), leading
to high levels of Notch1, Notch2, Jag1, and NICD expression
compared to the control group (Figure 4H). In accordance with
the results regarding Notch signaling function, the miR-29b
mimics inhibited in vitro osteogenic differentiation of BMMSCs,
as indicated by mineralized nodule formation and expression
of Runx2 and ALP (Figure 4I). These effects were partially atten-
uated by treatment with the Notch inhibitor, DAPT (Figure 4I).
These data suggest thatMSCT regulatesmiR-29b/Dnmt1/Notch
signaling to achieve long-term functional recovery of MRL/lpr
BMMSCs.
Exosomes Secreted Due to MSCT Rescue MRL/lpr
BMMSC Function
Next, we examined howMSCT regulated the levels of miR-29b in
recipient MRL/lpr BMMSCs. When MRL/lpr BMMSCs were co-
cultured with wild-type BMMSCs in a transwell system, elevated
intracellular levels of miR-29b; altered expression of Dnmt1,
Notch1, and NICD; and reduced in vitro osteogenic differentia-
tion in MRL/lpr BMMSCs were rescued, as assessed by real-
time PCR, western blot, and alizarin red staining, respectively
(Figures 5A, 5B, and S5A). These data suggest that wild-type
BMMSCs may release soluble factors or vesicles to regulate
MRL/lpr BMMSCs, perhaps by secreting exosomes. Exosomes
are small membrane vesicles (30–100 nm) of endocytic origin
that are constitutively released via fusion with the cell membrane
(The´ry et al., 2002). Exosomes can mediate local and systemic
cell-cell communications through the transfer of proteins,
mRNAs and microRNAs (Mittelbrunn and Sa´nchez-Madrid,
2012). In order to test whether BMMSCs secrete exosomes to
rescue MRL/lpr BMMSC function, we used a siRNA approach
to knockdown the expression of rab27a, a promoter for exosome
secretion, to block exosome secretion (Figures S5B and S5C)
(Ostrowski et al., 2010). We found that siRNA knockdown of
Rab27a attenuated BMMSC-mediated rescue of intracellular
levels of miR-29b and expression of Dnmt1, Notch1, and
NICD, as well as in vitro osteogenic differentiation in MRL/lpr
BMMSCs (Figures 5A, 5B, and S5A). In order to further evaluate
the role of exosomes in MSCT-mediated in vivo rescue of
recipient MRL/lpr BMMSCs, we revealed that knockdown of
Rab27a by siRNA blocked MSCT-induced reduction of intracel-
lular levels of miR-29b, upregulation of Dnmt1, and downregula-
tion of Notch1 and NICD, while elevating mineralized nodule
formation and upregulating Runx2 and ALP in MRL/lpr BMMSCs
(Figures 5C–5F).
Next, we evaluated the direct effects of exosomes on MRL/lpr
BMMSCs. We first confirmed that BMMSC-derived exosomes612 Cell Metabolism 22, 606–618, October 6, 2015 ª2015 Elsevier Inexpress CD63 and CD81 using western blot (Figure S5D).
When intravenously infused into MRL/lpr mice, exosomes were
detected in bone marrow cells at 24 hr postinfusion (Figure S5E).
When added to cultured MRL/lpr BMMSCs, exosomes were
taken in by BMMSCs (Figure S5F), and the levels of intracellular
miR-29b were reduced (Figure S5G), while Dnmt1 was upregu-
lated (Figure S5H), in vitro osteogenic differentiation was
improved (Figure S5I), and in vivo bone formation was increased
(Figure S5J). These data indicate that exosomes play an essen-
tial role in the regulation of miR-29b levels and rescue of MRL/lpr
BMMSC functions.
To verify whether exosomes exert therapeutic effects in vivo,
we infused exosomes into MRL/lpr mice and found that exo-
some infusion significantly reduced the intracellular levels of
miR-29b (Figure 5G), upregulated expression of Dnmt1 and
downregulated expression of Notch1 and NICD (Figure 5H),
elevated mineralized nodule formation and expression of
Runx2 and ALP (Figure 5I), and increased in vivo bone formation
(Figure 5J) in MRL/lpr BMMSCs. Exosome infusion produced
similar effects to those observed in MSCT groups. Moreover,
exosome infusion increased trabecular bone volume, BMD,
BV/TV, MAR, and BFR/BS inMRL/lprmice (Figures 5K and S5K).
MRL/lpr BMMSCs Reuse Fas, Provided by Donor
Exosomes, to Rescue Their Functions
We next aimed to gain insights into how exosomes regulate the
intracellular levels of miR-29b in recipient MRL/lpr BMMSCs.
Although MRL/lpr BMMSCs had elevated levels of intracellular
miR-29b, they showed reduced levels of miR-29b in culture me-
dium, serum, and bone marrow (Figures S6A–S6C). These
reduced levels of miR-29b were rescued by MSCT (Figures
S6A–S6C). We further revealed that MRL/lpr BMMSCs showed
reduced levels of the initial transcription product pri-miR-29b
(Figure S6D), suggesting that production ofmiR-29b is not signif-
icantly increased, but failure of MRL/lpr BMMSCs to release
miR-29b into the extracellular compartment may result in
increased intracellular levels and reduced extracellular levels of
miR-29b. Since MRL/lpr mice have a significant Fas deficiency
and it is known that Fas controls the MCP-1 secretion in
BMMSCs (Akiyama et al., 2012), we sought to determine
whether Fas controls miR-29b secretion in BMMSCs. We found
that siRNA knockdown of Fas in wild-type BMMSCs increased
the levels of intracellular miR-29b and decreased the levels of
extracellular miR-29b (Figures 6A, 6B, and S6E), the same as
observed in MRL/lpr BMMSCs. However, siRNA knockdown of
Fas in BMMSCs failed to significantly affect expression of pri-
miR-29b (Figure S6F). Meanwhile, overexpression of Fas in
MRL/lpr BMMSCs decreased the levels of intracellular miR-
29b and increased the levels of extracellular miR-29b (Figures
6C, 6D, and S6G), as was observed in MSCT-treated MRL/lpr
BMMSCs. Additionally, overexpression of Fas failed to signifi-
cantly affect the levels of pri-miR-29b (Figure S6H). These data
suggest that Fas may control miR-29b secretion in BMMSCs.
We next determinedwhether exosomes regulated the levels of
miR-29b through rescue of Fas-mediated miR-29b release in
MRL/lpr BMMSCs. We found that exosomes indeed contained
Fas protein (Figure S6I). More interestingly, in a coculture sys-
tem, exosomes from wild-type BMMSCs decreased intracellular
levels of miR-29b and increased extracellular levels of miR-29bc.
Figure 5. Exosomes Secreted Due to MSCT Downregulated Intracellular Levels of miR-29b in Recipient MRL/lpr BMMSCs
(A) Western blot showed Dnmt1, Notch1, and NICD expression in BMMSCs.
(B) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 4.
(C) Real-time PCR showed miR-29b expression in BMMSCs. n = 5.
(D) Western blot showed Dnmt1, Notch1, and NICD expression in BMMSCs.
(E) Alizarin red staining showed mineralized nodule formation of BMMSCs. n = 5.
(F) Western blot showed Runx2 and ALP expression in BMMSCs.
(G) Real-time PCR showed miR-29b expression in BMMSCs. n = 5.
(H) Western blot showed Dnmt1, Notch1, and NICD expression in BMMSCs.
(I) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 5. Western blot showed Runx2 and ALP expression in BMMSCs.
(J) H&E staining showed formation of new bone (B) and bonemarrow (BM) aroundHA/TCP (HA) carrier when BMMSCswere implanted into immunocompromised
mice. n = 5.
(K) mCT analysis of BMDand BV/TV of femurs. n = 5. All results are representative of data generated in three independent experiments. Statistical significancewas
determined with one-way ANOVA. **p < 0.01. Error bars are mean ± SD, 200 mm (J), 1 mm (K).in MRL/lpr BMMSCs (Figures 6E and 6F). However, exosomes
derived from MRL/lpr BMMSCs failed to reduce intracellular
miR-29b levels (Figures 6E and 6F). Exosomes derived from
MRL/lpr BMMSCs failed to rescue the osteoporotic phenotype
in MRL/lpr mice, as assessed by trabecular bone volume,
BMD, and BV/TV, when compared to exosomes derived from
wild-type BMMSCs (Figure 6G). Moreover, exosomes derived
fromMRL/lpr BMMSCs failed to rescue impaired osteogenic dif-
ferentiation of recipient MRL/lpr BMMSCs, as assessed by
mineralized nodule formation and the expression of Runx2 andCellALP (Figure 6H). These data indicate that Fas plays an essential
role in exosome-mediated recovery of miR-29b secretion.
We therefore hypothesized that exosomes may be able to
transfer functional Fas toMRL/lprBMMSCs to restore Fas-medi-
ated miR-29b release. To test this hypothesis, we transfected
BMMSCs with plasmids expressing Fas-enhanced green fluo-
rescent protein (Fas-eGFP) and used them to generate Fas-
eGFP exosomes (Figure S6J). We used immunofluorescent
staining and flow cytometric analysis to show that Fas-eGFP
fusion protein could be transferred to MRL/lpr BMMSCs afterMetabolism 22, 606–618, October 6, 2015 ª2015 Elsevier Inc. 613
Figure 6. Exosomes Rescued Intracellular Levels of miR-29b in MRL/lpr BMMSCs
(A–F) Real-time PCR showed miR-29b expression in BMMSCs under indicated conditions. n = 6.
(G) mCT analysis of BMD and BV/TV of femurs. n = 5.
(H) Alizarin red staining showed mineralized nodule formation by BMMSCs. n = 5. Western blot showed Runx2 and ALP expression in BMMSCs. All results are
representative of data generated in three independent experiments. Statistical significance was determined with two–tailed Student’s t tests (A–D) or one-way
ANOVA (E–H). **p < 0.01. Error bars are mean ± SD, 1 mm (G).treatment with Fas-eGFP-exosomes both in vitro and in vivo
(Figures 7A–7C). Interestingly, when lysosome inhibitor was
used to block lysosome functions, Fas-eGFP fusion protein
failed to locate on the BMMSCmembrane (Figure 7D). Therefore,
Fas reuse in MSCT appears to occur through nondirect mem-
brane fusion. In a transwell coculture system, activated T cells
were capable of inducing BMMSCs to undergo apoptosis via
the FasL/Fas pathway (Figures 7E and 7F). Due to the lack of
functional Fas in MRL/lpr BMMSCs, activated T cells failed to
induce them to undergo apoptosis (Figure 7G). However, treat-
ment with exosomes derived from either wild-type BMMSCs or
Fas-overexpressed MRL/lpr BMMSCs, but not from MRL/lpr
BMMSCs, restored the ability of activated T cells to induce
MRL/lpr BMMSC apoptosis (Figure 7G). This apoptosis process
was blocked by FasL neutralized antibody (Figure 7G). These re-
sults suggest that exosomes can transfer functional Fas to MRL/
lpr BMMSCs, leading to rescue of intracellular miR-29b release
and Fasl/Fas-mediated apoptosis. In order to evaluate whether
MSCT generated other therapeutic effects, we infused either
MSCs or exosomes into MRL/lprmice and examined their effect
on reducing lymph nodemass.We found that MSCT or exosome614 Cell Metabolism 22, 606–618, October 6, 2015 ª2015 Elsevier Ininfusion was able to reduce the size of the lymph nodes and
spleen at 4 and 8 weeks posttransplantation, respectively (Fig-
ures S7A–S7F). In addition, infusion of CD63-EGFP-labeled
BMMSCs or exosomes transferred Fas to T cells and restored
T cell apoptosis in MRL/lpr lymph nodes (Figures S7G–S7J).
DISCUSSION
Since the first cell-based therapy using hematopoietic stem cell
(HSC) transplantation was successfully performed in 1959 (Co-
pelan, 2006), HSCs, MSCs, and neural stem cells (NSCs) have
been used to treat various human diseases (Uccelli et al.,
2008). Althoughmultiple mechanisms, such as secretion of cyto-
kines/chemokines and cell-cell interactions, have been pro-
posed to be responsible for MSC-based immune therapies, it
has remained unclear whether cell-based therapies use epige-
netic regulation to achieve therapeutic effects. In this study, we
found that systemic MSCT rescued impaired recipient MRL/lpr
BMMSCs via regulation of DNA methylation status. This may
explain why administering MSCT once can provide long-time
therapeutic effects (Akiyama et al., 2012; Le Blanc et al., 2008;c.
Figure 7. MRL/lpr BMMSCs Reused Fas through Donor MSC-Released Exosomes
(A) Detection of EGFP+ and CD73+ cells among cultured BMMSCs by immunofluorescence and flow cytometric analysis after in vitro Fas-EGFP+ exosome
treatment. CD73 was used as a BMMSC marker for costaining.
(B) Detection of EGFP+ and CD73+ cells among cultured BMMSCs by immunofluorescence after in vivo Fas-EGFP+ exosome infusion.
(C) Detection of EGFP+ and CD73+ cells among cultured BMMSCs by immunofluorescence and flow cytometric analysis after in vivo Fas-EGFP+ exosome
infusion.
(D) After pretreatment with lysosome inhibitor and treatment with Fas-EGFP+ exosomes, EGFP+ and CD73+ cells among the BMMSCs were detected by
immunofluorescence.
(E) The reduced number of toluidine blue-positive cells indicated C3H/HeJ BMMSC apoptosis after direct coculture with activated spleen T cells.
(F) TUNEL staining (white arrows) of apoptotic BMMSCs.
(G) Toluidine blue staining of MRL/lpr BMMSCs cocultured with activated spleen T cells under indicated conditions. All results are representative of data
generated in three independent experiments. Error bars are 25 mm (A–C and F), 20 mm (D).Sun et al., 2009). Although we focused on epigenetic modifica-
tions to the recipient MRL/lpr BMMSCs, we could not exclude
the possibility that the MSCT triggered epigenetic modifications
in other types of cells in the recipient as well. Previous studies
showed that the T cells in human SLE patients and SLE mice
are also hypomethylated and exhibit downregulated expression
of DNMTs (Pan et al., 2010; Qin et al., 2013) while their levels of
Notch signaling are elevated (Teachey et al., 2008). Additional
experiments are required to examine whether MSCT offers ther-
apeutic benefits to immune cells in MRL/lpr mice.
A significant advantage of cell-based therapy is that the
infused cells exert therapeutic effects in multiple ways that are
responsive to different host microenvironments (Bernardo and
Fibbe, 2013; Li et al., 2012). These properties may account for
why MSCT has shown therapeutic effects in a variety of disease
conditions. In this study, we found MSCT rescued the global hy-
pomethylation pattern of the recipient BMMSCs, thereby using
epigenetic regulation to achieve a therapeutic effect. These find-Cellings indicate that other types of cell-based therapies may also
use epigenetic regulation as one of their therapeutic mecha-
nisms. MircoRNAs play a critical role in stem cell differentiation
and self-renewal. Emerging evidence indicates that multiple
miRNAs are capable of regulating the osteogenic differentiation
of MSCs and maintaining bone homeostasis (Clark et al., 2014;
Li et al., 2015). In this study, we reveal that recipient MSCs are
capable of receiving exosomes from donor MSCs and reusing
Fas derived from the exosomes to improve mir-29b release, re-
sulting in a recovery of a mir-29b-mediated epigenetic cascade
to improve recipient MSC function. Since we find Fas may con-
trol the release of multiple miRNAs in MSCs, and because exo-
somes contain a variety of miRNAs, it is possible that MSCT-
mediated exosome transfer may affect the function of multiple
miRNAs and miRNA-mediated epigenetic regulation.
Aberrations in exosome-mediated cell-cell communications
are believed to play an important role in the disease development
process (Luga et al., 2012; Peinado et al., 2012). Recent studiesMetabolism 22, 606–618, October 6, 2015 ª2015 Elsevier Inc. 615
indicate that tumor-derived exosomes are important tumorigen-
esis mediators capable of educating stromal/stem cells for
neoplastic transformation and tumor metastasis (Peinado et al.,
2012). Meanwhile, stromal cell-derived exosomes are able to
promote cancer cell migration (Luga et al., 2012). This evidence
suggests that exosomes play a crucial role in biological crosstalk
between tumor cells and surrounding stromal cells. Since exo-
somes serve as systemic cell-cell communication mediators,
we could not exclude their ‘‘off-target’’ effects on other organs.
Here we found MSCT or exosome infusion successfully reduced
lymph node mass in MRL/lpr mice through Fas reuse-mediated
T cell apoptosis. These results indicate that MSC-derived exo-
somes generate ‘‘off-target’’ effects andMSCTmay usemultiple
mechanisms to achieve therapeutic effects. MSCT-mediated
detailed therapeutic effects need to be further explored in the
future study. Given the crucial roles of miRNAs in regulating
gene expression and in disease development, miRNAs are re-
garded as potential therapeutic targets using chemically modi-
fied miRNA-targeting antisense oligonucleotides (Li and Rana,
2014). Previous studies showed that miR-29 regulates osteo-
blastic differentiation (Kapinas et al., 2010; Li et al., 2009). Here,
we found that miR-29b inhibitor treatment rescued the osteopo-
rotic phenotype and BMMSC-mediated new bone formation in
MRL/lpr mice. This evidence indicates that multiple miRNAs
other than miR-29b could be potential therapeutic targets for
intervention. Previous study demonstrated that MSCT could
transfer mitochondria to the recipient pulmonary alveoli (Islam
et al., 2012), suggesting that MSCT may provide organelles to
the recipient organs that assist in the rescue of the host cells.
Althoughwe reveal that the cellular component Fas can be trans-
ferred to the recipient MSCs in MRL/lpr mice and rescue their
impaired stem cell functions, it is unknown howFas is transferred
andhow long it canbe retained in the recipient cells. Also, itwill be
very interesting to understandwhetherMSCT-derived exosomes
can transfer cellular components other than Fas to the recipient
cells. Therefore, it is necessary to further explore detailed molec-
ular and cellular mechanisms in MSCT therapies, especially in
MSCT-mediated exosome transfer. Although it is unknown how
Fas is reused in recipient MRL/lpr BMMSCs after MSCT, it is
possible that intracellular metabolism, such as proteasome-
mediated degradation, contributes to the process of Fas reuse.
EXPERIMENTAL PROCEDURES
Mice
Female C3MRL-Faslpr/J (MRL/lpr) and C3H/HeJ mice were purchased from
the Jackson Laboratory (Bar Harbor, ME, USA). Female immunocompro-
mised mice (Beige XIDIII nude/nude) were purchased from Harlan (Denver,
CO, USA). All animal experiments were performed under institutionally
approved protocols for the use of animal research (University of Pennsyl-
vania IACUC# 805478 and University of Southern California IACUC
#11953).
Isolation of Mouse Bone Marrow Mesenchymal Stem Cells
A single suspension of bone marrow-derived all nucleated cells (ANCs) from
mouse femurs and tibias was seeded at a density of 2.53 105 cells per square
centimeter on 10 cm culture dish (Corning, NY, USA) at 37C in 5% CO2. Non-
adherent cells were removed after 48 hr, and attached cells were maintained
for 16 days in alpha minimum essential medium (a-MEM, Invitrogen) supple-
mented with 20% fetal bovine serum (FBS, Equitech-Bio, Kerrville, TX, USA),
2 mM L-glutamine, 55 mM 2-mercaptoethanol, 100 U/ml penicillin, and616 Cell Metabolism 22, 606–618, October 6, 2015 ª2015 Elsevier In100 mg/ml streptomycin (Invitrogen). Colonies forming attached cells were
passed once for further experimental use.BMMSC-Mediated Bone Formation In Vivo
Approximately 4.03 106 BMMSCs were mixed with hydroxyapatite/tricalcium
phosphate (HA/TCP) ceramic particles (40 mg, Zimmer, Warsaw, IN, USA) as a
carrier and subcutaneously implanted into the dorsal surface of 8- to 10-week-
old immunocompromised mice. At 8 weeks postimplantation, the implants
were harvested and were fixed with 4% paraformaldehyde (PFA) in phos-
phate-buffered saline (PBS), decalcified with 5% EDTA in PBS, then
embedded in paraffin. The 6 mm thick sections were stained with hematoxylin
and eosin (H&E). Images of the implants were analyzed using Image J software
(NIH). Five fields were selected, and the newly formed mineralized tissue area
in each field was calculated as a percentage of the total tissue area.Osteogenic Differentiation Assay
BMMSCs were cultured in osteogenic medium containing 2 mM b-glycero-
phosphate (Sigma), 100 mM L-ascorbicacid 2-phosphate (Sigma), and
10 nM dexamethasone (Sigma). Ten days after osteogenic induction, total pro-
tein was extracted from cultured BMMSCs and the expression of Runx2 and
ALP was assayed by western blot analysis. After 4 weeks of osteogenic
induction, the cultures were stained with 1% alizarin red-S (Sigma). Alizarin
red-positive area was analyzed using Image J software (NIH) and shown as
a percentage of alizarin red-positive area over total area.Mesenchymal Stem Cell Therapy
C3H/HeJ-derived BMMSCs at passage one were suspended in PBS (200 ml)
and infused into MRL/lpr mice (0.1 3 106 cells per 10 g body weight) intrave-
nously via the tail vein at 10 weeks of age. The MRL/lprmice infused with PBS
were used as MSCT controls. Background-matched C3H/HeJ mice infused
with PBSwere used as positive controls.Micewere sacrificed 7 days, 4weeks,
or 12 weeks after MSCT for further analysis.N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-Phenylglycine t-Butyl
Ester Treatments In Vitro and In Vivo
BMMSCs used for in vitro osteogenic differentiation were pretreated with
DAPT (1 mM, Sigma) or DMSO (mock) for 7 days. For BMMSC-mediated
bone formation in vivo, BMMSCs were pretreated with DAPT for 7 days and
subcutaneously implanted into immunocompromised mice as described
above. For in vivo study, mice were treated with 100 ml vehicle control (10%
ethanol, 90% corn oil) or DAPT (10 mg/kg of body weight, dissolved in 10%
ethanol, 90% corn oil) subcutaneously. A regimen of daily treatment was
continued for 3 days followed by 4 days without treatment. This weeklong
paradigm was repeated four times. Four weeks after the first treatment,
mice were sacrificed for further analysis.5-Azacytidine Treatments In Vitro and In Vivo
BMMSCs used for in vitro osteogenic differentiation were treated with 5-Aza-
cytidine (500 nM, Sigma) or PBS (mock) for 3 days. For in vivo study, 7 days
after MSCT, the mice were treated with 5-Azacytidine (0.5 mg/kg of body
weight, dissolved in PBS) or PBS (mock) subcutaneously for 7 days. Four
weeks after MSCT, mice were sacrificed for further analysis.Isolation, Characterization, and Labeling of Exosomes
Cells were cultured in exosome-depleted medium (complete medium
depleted of FBS-derived exosomes by overnight centrifugation at 100,000 g)
for 48 hr. Exosomes from culture supernatants were isolated by differential
centrifugation, as described in the literature (Thery et al., 2006), at 300 g for
10 min, 2,000 g for 10 min, 10,000 g for 30 min, and 100,000 g for 70 min, fol-
lowed by washing with PBS and purification by centrifugation at 100,000 g for
70 min. In each exosome preparation, the concentration of total proteins was
quantified using the Pierce BCA Protein Assay (Thermo). Purified exosomes
were characterized by western blot using anti-CD63 and CD81 antibodies.
PKH-26 (Sigma) was used for exosome labeling according to the manufac-
turer’s instructions.c.
Treatment with Exosomes
For in vitro treatment, BMMSCs were pretreated with exosomes (20 mg/ml) or
PBS (mock) for 3 days and then under osteoinductive culture conditions for
4 weeks. For BMMSC-mediated in vivo bone formation, BMMSCs were pre-
treated with exosomes (20 mg/ml) for 3 days and subcutaneously implanted
into immunocompromised mice as described above. For in vivo treatments,
exosomes (100 mg) suspended in 200 ml PBS or PBS (mock) were infused
into MRL/lpr mice intravenously by the tail vein. Four weeks after the treat-
ment, mice were sacrificed for further analysis. For in vivo exosome tracking,
PKH-26-labeled exosomes (100 mg) were infused into MRL/lpr mice intrave-
nously by the tail vein. At 24 hr postinfusion, the femurs were fixed in 4%
PFA and then decalcified with 5% ethylenediaminetetraacetic acid (EDTA), fol-
lowed by optimal cutting temperature compound (OCT, Sakura Finetek, Tor-
rance, CA, USA) embedding. Frozen sections were prepared, and slides
were mounted with Vectashield mounting medium containing 40,6-diami-
dino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA).
DNA Methylation and MicroRNA Microarray
Seven days after MSCT, BMMSCs derived fromC3H/HeJmice, MRL/lprmice,
and MRL/lprmice treated with MSCT were isolated and cultured as described
above. For DNA methylation microarray analysis, total DNA from cells at pas-
sage onewas extracted using aDNeasy Blood & Tissue Kit (QIAGEN, Valencia,
CA, USA) according to the manufacturer’s instructions. DNA methylation mi-
croarray (MeDIP-chip) and data processing were performed using Arraystar
(Rockville, MD, USA). For microRNA microarray analysis, total RNA from cells
at passage one was extracted using a miRNeasy Mini Kit (QIAGEN) according
to the manufacturer’s instructions. MicroRNA microarray and data processing
were performed by LC Sciences (Houston, TX, USA).
Immunofluorescent Staining
The BMMSCs were cultured on 4-well chamber slides (Nunc, Rochester, NY,
USA) (2 3 103/well) and treated with exosomes (20 mg/ml) derived from
BMMSCs transfected with plasmids containing Fas-EGFP fusion protein as
described above. The cells were then fixed with 4% paraformaldehyde. The
chamber slides were incubated with anti-GFP antibody (1:400) and anti-CD73
antibody (1:200) at 4C overnight followed by treatment with AlexaFluoro 488-
conjugatedsecondary antibody (1:400) andanti-rat IgG-PEsecondary antibody
(1:400) for 1 hr at room temperature. ActinGreen 488 Ready Probes Reagent
(Life Technologies) was used for cytoskeleton staining. Finally, slides were
mounted with Vectashield mounting medium containing DAPI. To evaluate the
role of lysosomes in protein reuse,MRL/lprBMMSCswere pretreatedwith lyso-
some inhibitor (Chloroquine, 200 mM, Sigma) for 6 hr before the treatment with
Fas-EGFP+ exosomes. For detection of Fas-EGFP fusion protein in vivo, Fas-
EGFP+ exosomes (100 mg) were infused into MRL/lpr mice intravenously by
the tail vein. After 24 hr of infusion, the single suspension of bone marrow-
derived cells from femurs and tibias was cultured. Five days after the culture,
the colonieswere used for immunofluorescent staining using antibodies against
GFP and CD73. After 24 hr of Fas-EGFP+ BMMSCs or Fas-EGFP+ exosome
infusion into MRL/lpr mice, the single suspension of cells in lymph nodes was
used for immunofluorescent staining using antibodies against GFP and CD3.
Statistics
SPSS 13.0 was used to perform statistical analysis. Group allocation, outcome
assessment, or animal studieswere not done in a blindedmanner.We selected
sample size based on our previous studies.(Akiyama et al., 2012; Liu et al.,
2011) The samples were excluded if any abnormality in terms of size, weight,
or apparent disease symptoms were observed in mice before performing ex-
periments. Since no abnormalities were observed in this study, no animals or
samples were excluded from analysis. Animals were randomly assigned
groups for studies. Data were assessed for normal distribution and similar vari-
ance between groups before further analysis. Significance was assessed by
independent two-tailedStudent’s t tests, analysis of variance (ANOVA). Bonfer-
roni correctionwas usedwhenmultiple comparisons were performed. p values
less than0.05were considered significant.Datawere expressedasmean±SD.
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